down arrow

Amylyx Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03237H1014
USD
12.50
0.48 (3.99%)

Dec 22

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.9212.60

52 Week

2.6016.96
Valuation
Technical
Day's Volume

CASH

1.6 M

Shareholding (Mar 2025)

FII

13.23%

Held by 100 FIIs

DII

50.24%

Held by 38 DIIs

Promoter

9.24%

How big is Amylyx Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Amylyx Pharmaceuticals, Inc. has a market capitalization of 475.12 million, classifying it as a Micro Cap company, with net sales of -1.27 million and a net profit of -218.86 million over the latest four quarters. Shareholder's funds are 164.76 million, and total assets are 193.63 million.

Market Cap: As of Jun 18, Amylyx Pharmaceuticals, Inc. has a market capitalization of 475.12 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Amylyx Pharmaceuticals, Inc. reported net sales of -1.27 million and a net profit of -218.86 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 164.76 million, while total assets were reported at 193.63 million.

Read More

What does Amylyx Pharmaceuticals, Inc. do?

22-Jun-2025

Amylyx Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $36 million and a market cap of $475.12 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -79.34%.

Overview: <BR>Amylyx Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -36 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 475.12 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -79.34% <BR>Price to Book: 2.36<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Amylyx Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 8, 2025, Amylyx Pharmaceuticals is considered overvalued and has been downgraded to "does not qualify" due to poor financial metrics, including a price-to-book ratio of 2.36 and an ROE of -79.34%, while significantly underperforming its peers despite a strong one-year stock return of 182.02%.

As of 8 May 2025, the valuation grade for Amylyx Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently overvalued given its financial metrics, particularly with a price-to-book value of 2.36 and a return on equity (ROE) of -79.34%. Additionally, the EV to EBITDA ratio stands at -1.60, reflecting substantial operational challenges.<BR><BR>In comparison to its peers, Amylyx Pharmaceuticals is underperforming significantly. For instance, Catalyst Pharmaceuticals, Inc. has a P/E ratio of 14.87 and an EV to EBITDA of 8.36, while Supernus Pharmaceuticals, Inc. shows a P/E of 28.13 and an EV to EBITDA of 8.72. These comparisons highlight that Amylyx is not only lagging behind its competitors but also carries a valuation that does not justify its current price level. Furthermore, despite a strong one-year stock return of 182.02%, the recent performance has been poor relative to the S&P 500, which suggests that the stock may not sustain its current valuation.

Read More

Is Amylyx Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of June 24, 2025, Amylyx Pharmaceuticals, Inc. shows a bullish technical trend with strong momentum indicators and significant outperformance against the S&P 500, boasting a year-to-date return of 250.53% compared to the S&P's 12.22%.

As of 24 June 2025, the technical trend for Amylyx Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages are also bullish. However, the weekly RSI is bearish, and the monthly RSI shows no signal. The KST is bullish for both weekly and monthly periods, and Dow Theory indicates a mildly bullish stance on both time frames. The OBV is mildly bullish as well.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 250.53% compared to the S&P 500's 12.22%, and a one-year return of 360.07% versus 17.14%. Overall, the current technical stance is bullish, supported by strong momentum indicators and significant outperformance against the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 931 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.07

stock-summary
Return on Equity

-90.18%

stock-summary
Price to Book

5.55

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-41 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.09%
0%
-6.09%
6 Months
147.52%
0%
147.52%
1 Year
208.64%
0%
208.64%
2 Years
-13.79%
0%
-13.79%
3 Years
-65.43%
0%
-65.43%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Amylyx Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-9.14%
EBIT Growth (5y)
-2.71%
EBIT to Interest (avg)
-136.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.62
Tax Ratio
0.29%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.36
EV to EBIT
-1.59
EV to EBITDA
-1.60
EV to Capital Employed
-170.49
EV to Sales
-213.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-79.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 52 Schemes (27.29%)

Foreign Institutions

Held by 100 Foreign Institutions (13.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 100.00% vs -101.02% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 43.05% vs -428.96% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "-1.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.70",
          "val2": "-53.20",
          "chgp": "19.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-22.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.40",
          "val2": "-72.70",
          "chgp": "43.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -77.05% vs 1,615.32% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -711.97% vs 124.85% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "87.40",
          "val2": "380.80",
          "chgp": "-77.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-254.80",
          "val2": "39.90",
          "chgp": "-738.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-59.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-301.70",
          "val2": "49.30",
          "chgp": "-711.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,926.30%",
          "val2": "101.90%",
          "chgp": "-302.82%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
-1.00
100.00%
Operating Profit (PBDIT) excl Other Income
-42.70
-53.20
19.74%
Interest
0.00
0.00
Exceptional Items
0.00
-22.90
100.00%
Consolidate Net Profit
-41.40
-72.70
43.05%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 100.00% vs -101.02% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 43.05% vs -428.96% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
87.40
380.80
-77.05%
Operating Profit (PBDIT) excl Other Income
-254.80
39.90
-738.60%
Interest
0.00
0.00
Exceptional Items
-59.10
0.00
Consolidate Net Profit
-301.70
49.30
-711.97%
Operating Profit Margin (Excl OI)
-2,926.30%
101.90%
-302.82%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -77.05% vs 1,615.32% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -711.97% vs 124.85% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Amylyx Pharmaceuticals, Inc. stock-summary
stock-summary
Amylyx Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."